Morgan Lee Lekstrom Purchases 34,000 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom purchased 34,000 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were acquired at an average price of $1.47 per share, for a total transaction of $49,980.00. Following the purchase, the chairman directly owned 309,000 shares in the company, valued at approximately $454,230. The trade was a 12.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 21st, Morgan Lee Lekstrom purchased 147,000 shares of Biosig Technologies stock. The shares were acquired at an average price of $1.04 per share, for a total transaction of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.

Biosig Technologies Price Performance

Shares of Biosig Technologies stock opened at $1.51 on Friday. The stock’s fifty day simple moving average is $1.13. The stock has a market cap of $274.52 million, a PE ratio of -0.16 and a beta of 1.58. Biosig Technologies, Inc. has a 1-year low of $0.70 and a 1-year high of $14.11.

Biosig Technologies (NASDAQ:STEX) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Needham & Company LLC lowered their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, May 21st. Weiss Ratings upgraded shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. Finally, Wall Street Zen cut shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research note on Sunday, April 5th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.